Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 18/20 | 0.75 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837221 | 0.91 | MAPK1 (0.76) | MAPK1MAPK3KCNH2NUAK1CCNE1 | |
| SCHEMBL17837268 | 0.91 | MAPK1 (0.73) | MAPK1MAPK3KCNH2 | |
| SCHEMBL17837231 | 0.91 | MAPK1 (0.75) | MAPK1MAPK3 | |
| Temuterkib SCHEMBL17837273 | 0.85 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL17837306 | 0.83 | MAPK1 (0.94) | MAPK1MAPK3 | |
| SCHEMBL17837173 | 0.82 | MAPK1 (0.52) | MAPK1MAPK3CDK2 | |
| Temuterkib SCHEMBL28928408 | 0.81 | MAPK1 (0.91) | MAPK1MAPK3 | |
| SCHEMBL17856234 | 0.81 | MAPK3 (0.50) | MAPK1MAPK3CDK2CDK4CCND1 | |
| SCHEMBL17837226 | 0.81 | MAPK3 (0.49) | MAPK1MAPK3CDK2CDK4CCND1 | |
| Hydrochloric Acid SCHEMBL17837235 | 0.81 | MAPK3 (0.49) | MAPK1MAPK3CDK2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20160375030-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-12-29 | — | — | US | disclosed |
| US-20160375030-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-12-29 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375030-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK1 2/4885MAPK3 3/4885KCNH2 4546/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK1 2/4885MAPK3 3/4885KCNH2 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.